Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib, TQB2450, and Albumin-bound Paclitaxel in CLDN18.2-failed GC/GEJA
NCT06222944Phase 2Not yet recruiting
- Sponsor
- Peking University
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, benmelstobart in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Peking University. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06222944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222944.